## **Supplementary Material**

## Method Optimisation in Hydrophilic Interaction Liquid Chromatography by Design of Experiments Combined with Quantitative Structure-Retention Relationships\*

## Maryam Taraji<sup>A,B,C</sup> and Paul R. Haddad<sup>C,D</sup>

<sup>A</sup>The Australian Wine Research Institute, PO Box 197, Adelaide, SA 5064, Australia. <sup>B</sup>Metabolomics Australia, PO Box 197, Adelaide, SA 5064, Australia. <sup>c</sup>Australian Centre for Research on Separation Science, School of Natural Sciences, University of Tasmania, Private Bag 75, Hobart, Tas. 7001, Australia. <sup>D</sup>Corresponding author. Email: Paul.Haddad@utas.edu.au Contents:

Table S1. Plan of experiments defined by the two-level full factorial design.

Table S2. Coefficients of the obtained DoE models for 16 nucleosides and their statistical evaluation on zwitterionic column.

Table S3. Coefficients of the obtained DoE models for 16 nucleosides and their statistical evaluation on amide column.

Table S4. Coefficients of the obtained DoE models for 16 nucleosides and their statistical evaluation on amine column.

Table S5. Coefficients of the obtained DoE models for 16 nucleosides and their statistical evaluation on bare silica column.

Figure S1. DoE model term ranking chart for 16 nucleosides over (A) zwitterionic, (B) amide, (C) amine, and (D) bare silica systems.

Table S6. Predictive performance of local GA-PLS models on internal validation under all 11 mobile phase compositions corresponding to the used DOE and over zwitterionic, amide, amine, and bare silica HILIC stationary phases.

Table S7. The predicted retention times of test compounds on the chromatographic conditions corresponding to the used DoE matrix over zwitterionic HILIC column by using QSRR-DOE models.

Table S8. The predicted retention times of test compounds on the chromatographic conditions corresponding to the used DoE matrix over amide HILIC column by using QSRR-DOE models.

Table S9. The predicted retention times of test compounds on the chromatographic conditions corresponding to the used DoE matrix over amine HILIC column by using QSRR-DOE models.

Table S10. The predicted retention times of test compounds on the chromatographic conditions corresponding to the used DoE matrix over bare silica HILIC column by using QSRR-DOE models.

Figure S2. The residual plots of prediction errors using dual-filtering-based GA-PLS models for test set of 16 nucleosides over all experimental conditions corresponding to the used DOE matrix for (A) zwitterionic, (B) amide, (C) amine, and (D) bare silica systems.

Table S11. The experimental retention data and predicted retention times of test compounds on the selected working conditions over zwitterionic, amide, amine, and bare silica HILIC columns by using QSRR-DOE models.

nr.	Acentonitrile co	ntipH	Salt concentration
1	70	3	10
2	90	3	10
3	70	7	10
4	90	7	10
5	70	3	20
6	90	3	20
7	70	7	20
8	90	7	20
9	80	5	15
10	80	5	15
11	80	5	15

Table S1. Plan of experiments defined by two-level full factorial design.

Table S2. Coefficients of the obtained DoE models for 16 nucleosides and their statistical evaluation on zwitterionic column.

Name of	β <sub>o</sub>	β1	β <sub>2</sub>	β₃	β4	Q <sup>2</sup>	R <sup>2</sup>	R <sup>2</sup> adj.
compounds	(p)	(p)	(p)	(p)	(p)			
2'-Deoxyadenosine	3.23 (0.00)	1.32 (0.00)	0.08 (0.00)	0.64 (0.00)	0.07 (0.00)	1.00	1.00	1.00
2'-Deoxycytidine	4.44 (0.00)	4.38 (0.00)	0.70 (0.00)	3.06 (0.00)	0.68 (0.00)	0.99	1.00	1.00
2',3'- Dideoxyadenosine	2.86 (0.00)	0.73 (0.00)	0.00	0.28 (0.00)	0.00	0.95	0.99	0.98
2'-Deoxyguanosine	4.38 (0.00)	4.88 (0.00)	0.67 (0.01)	3.47 (0.00)	0.66 (0.01)	0.98	0.99	0.99
3'-Deoxyguanosine	4.15 (0.00)	4.39 (0.00)	0.59 (0.01)	3.12 (0.00)	0.59 (0.01)	0.98	0.99	0.99
5'-Methyluridine	2.98 (0.00)	1.36 (0.00)	0.25 (0.00)	0.80 (0.00)	0.25 (0.00)	0.98	0.99	0.99
Adenosine	3.50 (0.00)	1.94 (0.00)	0.23 (0.00)	1.11 (0.00)	0.23 (0.00)	1.00	1.00	1.00
Cytidine	5.01 (0.00)	6.84 (0.00)	1.62 (0.00)	5.15 (0.00)	1.60 (0.00)	0.99	1.00	1.00
Guanosine	4.95 (0.00)	7.45 (0.00)	1.43 (0.01)	5.66 (0.00)	1.43 (0.01)	0.96	0.99	0.98
Inosine	4.23 (0.00)	4.35 (0.00)	0.97 (0.00)	3.03 (0.00)	0.96 (0.00)	0.97	0.99	0.99
Thymidine	2.66 (0.00)	0.75 (0.00)	0.08 (0.00)	0.37 (0.00)	0.09 (0.00)	0.99	1.00	0.99
Uridine	3.28 (0.00)	1.85 (0.00)	0.41 (0.00)	1.14 (0.00)	0.40 (0.00)	0.97	0.99	0.99
Acyclovir	4.21 (0.00)	4.03 (0.00)	0.60 (0.00)	2.79 (0.00)	0.63 (0.00)	0.98	1.00	0.99
2'-Deoxyuridine	2.89 (0.00)	1.03 (0.00)	0.16 (0.01)	0.56 (0.00)	0.19 (0.00)	0.97	0.99	0.99
3'-Deoxythymidine	2.27 (0.00)	0.31 (0.00)	0.00	0.13 (0.00)	0.00	0.98	0.99	0.99
2'-Deoxyinosine	3.79 (0.00)	2.91 (0.00)	0.52 (0.00)	1.89 (0.00)	0.54 (0.00)	0.97	0.99	0.99

Table S3. Coefficients of the obtained DoE models for 16 nucleosides and their statistical evaluation on amide column.

	0	0	0	0	0	-2	_2	-2
Name of	₿ <sub>0</sub>	β <sub>1</sub>	B <sub>2</sub>	B <sub>3</sub>	$\boldsymbol{\beta}_4$	Q	R <sup>2</sup>	R <sup>-</sup> adj.
compounds	(p)	(p)	(p)	(p)	(p)			
2'-Deoxyadenosine	3.15 (0.00)	1.11 (0.00)	0.06 (0.00)	0.57 (0.00)	0.06 (0.00)	1.00	1.00	1.00
2'-Deoxycytidine	4.32 (0.00)	3.87 (0.00)	0.00	2.56 (0.00)	0.00	0.99	0.99	0.99
2',3'- Dideoxyadenosine	2.95 (0.00)	0.72 (0.00)	0.02 (0.02)	0.33 (0.00)	0.00	1.00	1.00	1.00
2'-Deoxyguanosine	3.94 (0.00)	3.23 (0.00)	0.24 (0.00)	2.18 (0.00)	0.28 (0.00)	1.00	1.00	1.00
3'-Deoxyguanosine	3.86 (0.00)	3.12 (0.00)	0.24 (0.00)	2.13 (0.00)	0.29 (0.00)	1.00	1.00	1.00
5'-Methyluridine	2.89 (0.00)	0.93 (0.00)	0.09 (0.00)	0.51 (0.00)	0.10 (0.00)	1.00	1.00	1.00
Adenosine	3.34 (0.00)	1.49 (0.00)	0.12 (0.00)	0.84 (0.00)	0.13 (0.00)	1.00	1.00	1.00
Cytidine	4.55 (0.00)	4.78 (0.00)	0.34 (0.00)	3.31 (0.00)	0.40 (0.00)	1.00	1.00	1.00
Guanosine	4.26 (0.00)	4.33 (0.00)	0.40 (0.00)	3.08 (0.00)	0.48 (0.00)	1.00	1.00	1.00
Inosine	3.58 (0.00)	2.37 (0.00)	0.25 (0.00)	1.52 (0.00)	0.29 (0.00)	1.00	1.00	1.00
Thymidine	2.70 (0.00)	0.62 (0.00)	0.05 (0.00)	0.30 (0.00)	0.05 (0.00)	1.00	1.00	1.00
Uridine	2.95 (0.00)	1.02 (0.00)	0.11 (0.00)	0.56 (0.00)	0.13 (0.00)	1.00	1.00	1.00
Acyclovir	3.68 (0.00)	2.53 (0.00)	0.23 (0.00)	1.65 (0.00)	0.27 (0.00)	0.99	0.99	0.99
2'-Deoxyuridine	2.77 (0.00)	0.71 (0.00)	0.07 (0.00)	0.34 (0.00)	0.07 (0.00)	0.99	1.00	0.99
3'-Deoxythymidine	2.48 (0.00)	0.33 (0.00)	0.02 (0.01)	0.14 (0.00)	0.01 (0.03)	0.99	1.00	1.00
2'-Deoxyinosine	3.37 (0.00)	1.79 (0.00)	0.18 (0.00)	1.08 (0.00)	0.21 (0.00)	0.98	0.99	0.99

Table S4. Coefficients of the obtained DoE models for 16 nucleosides and their statistical evaluation on amine
column.

Name of	β <sub>o</sub>	βı	β <sub>2</sub>	β₃	β4	Q <sup>2</sup>	R <sup>2</sup>	R <sup>2</sup> adj.
compounds	(p)	(p)	(p)	(p)	(p)			
2'-Deoxyadenosine	3.34 (0.00)	1.43 (0.00)	0.23 (0.00)	0.74 (0.00)	0.18 (0.00)	0.99	1.00	0.99
2'-Deoxycytidine	4.96 (0.00)	5.30 (0.00)	1.35 (0.00)	3.64 (0.00)	1.29 (0.00)	1.00	1.00	1.00
2',3'- Dideoxyadenosine	2.91 (0.00)	0.81 (0.00)	0.09 (0.02)	0.36 (0.00)	0.00	0.98	0.99	0.99
2'-Deoxyguanosine	4.87 (0.00)	5.82 (0.00)	1.49 (0.00)	4.27 (0.00)	1.45 (0.00)	0.99	1.00	1.00
3'-Deoxyguanosine	4.62 (0.00)	5.33 (0.00)	1.36 (0.00)	3.94 (0.00)	1.31 (0.00)	0.98	1.00	0.99
5'-Methyluridine	3.29 (0.00)	1.80 (0.00)	0.56 (0.00)	1.19 (0.00)	0.53 (0.00)	0.98	0.99	0.99
Adenosine	3.71 (0.00)	2.25 (0.00)	0.59 (0.00)	1.40 (0.00)	0.54 (0.00)	0.99	1.00	0.99
Cytidine	5.89 (0.00)	9.30 (0.00)	3.57 (0.00)	7.16 (0.00)	3.48 (0.00)	0.90	0.98	0.96
Guanosine	5.69 (0.00)	9.53 (0.00)	3.48 (0.00)	7.64 (0.00)	3.31 (0.00)	0.92	0.98	0.97
Inosine	4.98 (0.00)	5.94 (0.00)	2.18 (0.00)	4.40 (0.00)	2.14 (0.00)	0.95	0.99	0.98
Thymidine	2.85 (0.00)	0.95 (0.00)	0.28 (0.00)	0.56 (0.00)	0.22 (0.00)	0.97	0.99	0.99
Uridine	3.64 (0.00)	2.44 (0.00)	0.99 (0.00)	1.72 (0.00)	0.91 (0.00)	0.93	0.98	0.97
Acyclovir	4.67 (0.00)	3.95 (0.00)	0.00	2.61 (0.00)	0.00	0.90	0.95	0.93
2'-Deoxyuridine	3.12 (0.00)	1.00 (0.00)	0.00	0.56 (0.02)	0.00	0.86	0.95	0.92
3'-Deoxythymidine	2.55 (0.00)	0.30 (0.00)	0.00	0.00	0.00	0.51	0.68	0.65
2'-Deoxyinosine	4.33 (0.00)	2.87 (0.00)	0.00	1.93 (0.00)	0.00	0.89	0.96	0.94

Table S5. C	Coefficients of the obtained DoE models for 16 nucleosides and their statistical evaluation on bare silica	
column.		

Name of	β <sub>o</sub>	β1	β <sub>2</sub>	β₃	β4	Q <sup>2</sup>	R <sup>2</sup>	R <sup>2</sup> adj.
compounds	(p)	(p)	(p)	(p)	(p)			
2'-Deoxyadenosine	1.74 (0.00)	0.61 (0.00)	0.04 (0.02)	0.30 (0.00)	0.00	0.99	1.00	1.00
2'-Deoxycytidine	2.05 (0.00)	1.93 (0.00)	0.50 (0.00)	1.41 (0.00)	0.49 (0.00)	0.94	0.99	0.98
2',3'- Dideoxyadenosine	1.72 (0.00)	0.39 (0.00)	0.00	0.14 (0.01)	0.00	0.95	0.97	0.96
2'-Deoxyguanosine	1.89 (0.00)	1.77 (0.00)	0.52 (0.00)	1.30 (0.00)	0.50 (0.00)	0.93	0.98	0.97
3'-Deoxyguanosine	1.82 (0.00)	1.58 (0.00)	0.47 (0.00)	1.17 (0.00)	0.46 (0.00)	0.93	0.98	0.97
5'-Methyluridine	1.44 (0.00)	0.51 (0.00)	0.19 (0.00)	0.32 (0.01)	0.17 (0.00)	0.90	0.98	0.96
Adenosine	1.76 (0.00)	0.81 (0.00)	0.17 (0.01)	0.47 (0.00)	0.15 (0.01)	0.96	0.99	0.98
Cytidine	2.14 (0.00)	2.83 (0.00)	1.11 (0.01)	2.24 (0.01)	1.09 (0.01)	0.83	0.96	0.93
Guanosine	1.96 (0.00)	2.50 (0.00)	1.02 (0.01)	1.98 (0.01)	1.00 (0.01)	0.85	0.96	0.94
Inosine	1.85 (0.00)	1.71 (0.00)	0.69 (0.01)	1.27 (0.02)	0.67 (0.02)	0.79	0.95	0.91
Thymidine	1.40 (0.00)	0.30 (0.00)	0.08 (0.02)	0.13 (0.03)	0.06 (0.04)	0.90	0.97	0.95
Uridine	1.53 (0.00)	0.69 (0.00)	0.30 (0.01)	0.44 (0.02)	0.28 (0.01)	0.81	0.95	0.92
Acyclovir	2.03 (0.00)	1.63 (0.00)	0.43 (0.00)	1.11 (0.00)	0.40 (0.00)	0.95	0.99	0.98
2'-Deoxyuridine	1.49 (0.00)	0.39 (0.00)	0.13 (0.01)	0.00	0.10 (0.03)	0.87	0.96	0.93
3'-Deoxythymidine	1.35 (0.00)	0.13 (0.00)	0.00	0.00	0.00	0.74	0.79	0.77
2'-Deoxyinosine	1.86 (0.00)	1.19 (0.00)	0.34 (0.01)	0.75 (0.00)	0.31 (0.01)	0.91	0.98	0.96



Figure S1. DoE model term ranking chart for 16 nucleosides over (A) zwitterionic, (B) amide, (C) amine, and (D) bare silica systems.

Table S6. Predictive performance of local GA-PLS models on internal validation under	Il 11 mobile phase compositions corresponding to the used DOE and over zwitterionic, amide, amine,
and bare silica HILIC stationary phases.	

	Zwitte	rionic	ami	de	ami	ne	baresilica		
	RMSECV	Q <sup>2</sup> <sub>cv</sub>	RMSECV	Q <sup>2</sup> <sub>cv</sub>	RMSECV	Q <sup>2</sup> <sub>cv</sub>	RMSECV	Q <sup>2</sup> <sub>cv</sub>	
1	0.01	0.99	0.00	0.99	0.01	0.99	0.01	0.99	
2	0.09	0.98	0.09	0.98	0.12	0.98	0.04	0.99	
3	0.01	0.99	0.01	0.99	0.99 0.01		0.00	0.99	
4	0.16	0.97	0.06	0.99	0.10	0.98	0.03	0.99	
5	0.01	0.99	0.01	0.98	0.03	0.97	0.01	0.99	
6	0.17	0.98	0.09	0.98	0.31	0.98	0.09	0.98	
7	0.01	0.98	0.01	0.99	0.01	0.99	0.01	0.99	
8	0.18	0.98	0.07	0.99	0.21	0.99	0.12	0.99	
9	0.02	0.98	0.02	0.99	0.03	0.98	0.01	0.99	
10	0.02	0.99	0.02	0.98	0.02	0.98	0.01	0.99	
11	0.02	0.99	0.02	0.98	0.02	0.99	0.01	0.99	
Average	0.06	0.98	0.03	0.98	0.08	0.98	0.03	0.99	

ino dello.											
					Predicte	d Retentior	Factors				
	<i>K</i> 1	К 2	КЗ	<i>K</i> 4	К5	К6	К7	К8	К9	<i>K</i> 10	<i>K</i> 11
2'-Deoxyadenosine	0.58	1.74	0.63	2.01	0.60	2.13	0.64	2.34	0.94	0.93	0.94
2'-Deoxycytidine	0.97	4.97	0.92	5.49	1.01	7.19	0.96	7.05	1.74	1.81	1.79
2',3'-Dideoxyadenosine	0.57	1.53	0.53	1.37	0.57	1.71	0.57	1.45	0.94	0.87	0.90
2'-Deoxyguanosine	0.87	5.30	0.93	5.90	0.93	8.23	0.96	8.75	1.77	1.86	1.82
3'-Deoxyguanosine	0.83	5.09	0.95	6.46	0.89	7.40	0.96	7.10	1.73	1.84	1.78
5'-Methyluridine	0.54	1.74	0.55	2.07	0.56	2.76	0.60	2.70	0.91	0.97	0.95
Adenosine	0.65	2.50	0.67	2.52	0.69	3.02	0.72	3.04	1.20	1.21	1.21
Cytidine	1.09	6.45	0.98	7.56	1.08	11.68	1.09	11.67	1.90	2.01	2.01
Guanosine	0.84	5.98	0.98	8.92	0.98	10.81	0.93	10.84	1.86	2.00	1.83
Inosine	0.89	5.72	0.92	6.08	0.86	7.80	1.01	7.22	1.66	1.80	1.92
Thymidine	0.43	1.12	0.51	1.25	0.46	1.45	0.49	1.43	0.66	0.67	0.68
Uridine	0.55	1.92	0.66	2.21	0.59	3.74	0.63	2.92	0.95	1.02	0.97
Acyclovir	0.82	4.14	0.93	5.22	0.86	6.34	0.91	6.06	1.47	1.54	1.57
2'-Deoxyuridine	0.51	1.35	0.56	1.65	0.53	2.20	0.58	2.08	0.82	0.84	0.85
3'-Deoxythymidine	0.39	0.57	0.40	0.75	0.41	0.90	0.44	0.90	0.57	0.57	0.52
2'-Deoxvinosine	0.71	3.07	0.80	3.45	0.77	4.69	0.81	5.01	1.35	1.41	1.39

Table S7. The predicted retention times of test compounds on the chromatographic conditions corresponding to the used DoE matrix over zwitterionic HILIC column by using QSRR-DOE models.

					Predicted	d Retentior	n Factors				
_	<i>K</i> 1	К2	КЗ	К4	К5	К6	К7	К8	К9	<i>K</i> 10	<i>K</i> 11
2'-Deoxyadenosine	0.41	1.42	0.41	1.54	0.40	1.59	0.44	1.74	0.72	0.68	0.66
2'-Deoxycytidine	0.57	4.02	0.59	3.82	0.56	4.65	0.63	4.48	1.23	1.18	1.14
2',3'-Dideoxyadenosine	0.39	0.98	0.37	1.24	0.39	1.33	0.40	1.26	0.68	0.65	0.61
2'-Deoxyguanosine	0.58	4.07	0.59	4.01	0.58	4.27	0.62	4.32	1.25	1.20	1.15
3'-Deoxyguanosine	0.56	3.61	0.55	3.43	0.55	4.27	0.58	4.25	1.11	1.10	1.05
5'-Methyluridine	0.35	1.21	0.33	1.19	0.34	1.53	0.35	1.40	0.59	0.58	0.56
Adenosine	0.44	1.71	0.43	1.73	0.43	1.98	0.46	1.98	0.83	0.80	0.77
Cytidine	0.63	5.34	0.67	5.18	0.63	5.93	0.74	6.02	1.51	1.46	1.39
Guanosine	0.61	4.47	0.61	4.50	0.60	5.70	0.65	5.42	1.11	1.07	1.03
Inosine	0.55	3.19	0.52	3.19	0.51	3.81	0.53	3.77	1.24	1.21	1.18
Thymidine	0.32	0.89	0.28	0.96	0.31	1.09	0.33	1.04	0.48	0.48	0.46
Uridine	0.35	1.28	0.34	1.29	0.34	1.51	0.36	1.55	0.61	0.60	0.58
Acyclovir	0.55	3.29	0.60	3.23	0.55	3.56	0.60	4.01	1.12	1.11	1.02
2'-Deoxyuridine	0.31	0.97	0.30	0.95	0.31	1.10	0.32	1.14	0.52	0.51	0.49
3'-Deoxythymidine	0.27	0.56	0.27	0.60	0.26	0.63	0.28	0.70	0.40	0.40	0.40
2'-Deoxyinosine	0.45	2.14	0.44	2.09	0.44	2.46	0.47	2.72	0.86	0.85	0.81

Table S8. The predicted retention times of test compounds on the chromatographic conditions corresponding to the used DoE matrix over amide HILIC column by using QSRR-DOE models.

		Predicted Retention Factors											
_	<i>K</i> 1	К 2	КЗ	К4	<i>K</i> 5	К6	К7	<i>K</i> 8	К9	<i>K</i> 10	<i>K</i> 11		
2'-Deoxyadenosine	0.66	1.73	0.72	1.91	0.70	2.34	0.71	2.33	0.98	0.96	0.98		
2'-Deoxycytidine	1.11	5.54	1.23	5.28	1.01	9.05	1.20	8.34	2.12	2.05	2.04		
2',3'-Dideoxyadenosine	0.62	1.58	0.61	1.36	0.65	1.41	0.61	1.58	0.91	0.93	0.91		
2'-Deoxyguanosine	1.15	6.16	1.24	6.05	1.15	10.97	1.20	9.45	2.20	2.07	2.08		
3'-Deoxyguanosine	1.20	6.03	1.23	5.86	1.32	10.18	1.17	8.45	2.21	2.05	2.05		
5'-Methyluridine	0.75	2.10	0.76	1.88	0.72	3.39	0.78	3.37	1.15	1.10	1.09		
Adenosine	0.82	2.47	0.84	2.48	0.76	4.06	0.84	3.54	1.30	1.30	1.27		
Cytidine	1.25	8.11	1.35	7.52	1.19	16.35	1.37	13.13	2.45	2.51	2.27		
Guanosine	1.23	7.21	1.29	7.00	1.29	16.61	1.26	12.82	2.42	2.24	2.10		
Inosine	1.23	5.21	1.33	5.72	1.26	12.23	1.28	10.11	2.22	2.08	2.22		
Thymidine	0.60	1.27	0.60	1.29	0.68	1.70	0.57	1.67	0.76	0.77	0.75		
Uridine	0.80	2.20	0.82	2.06	0.92	3.90	0.79	3.70	1.22	1.17	1.09		
Acyclovir	0.98	4.62	1.12	4.65	0.99	6.24	1.08	6.01	1.77	1.74	1.84		
2'-Deoxyuridine	0.70	1.65	0.69	1.56	0.82	2.40	0.70	2.09	0.97	0.95	0.96		
3'-Deoxythymidine	0.51	0.91	0.53	0.74	0.62	0.97	0.50	0.90	0.67	0.57	0.54		
2'-Deoxyinosine	0.99	3.77	1.12	3.88	1.86	5.20	1.07	4.54	1.79	1.67	1.64		

Table S9. The predicted retention times of test compounds on the chromatographic conditions corresponding to the used DoE matrix over amine HILIC column by using QSRR-DOE models.

	Predicted Retention Factors										
	<i>K</i> 1	К 2	КЗ	<i>K</i> 4	К5	К6	К7	<i>K</i> 8	К9	<i>K</i> 10	<i>K</i> 11
2'-Deoxyadenosine	0.44	1.41	0.46	1.50	0.47	1.56	0.47	1.79	0.71	0.67	0.70
2'-Deoxycytidine	0.54	3.23	0.54	3.37	0.57	5.13	0.56	6.20	1.04	1.00	1.04
2',3'-Dideoxyadenosine	0.44	1.43	0.48	1.29	0.48	1.40	0.44	1.12	0.74	0.69	0.73
2'-Deoxyguanosine	0.43	2.88	0.48	3.10	0.47	4.86	0.51	6.16	0.92	0.87	0.92
3'-Deoxyguanosine	0.40	2.69	0.44	3.00	0.46	4.70	0.49	5.62	0.90	0.88	0.91
5'-Methyluridine	0.24	0.89	0.28	0.94	0.24	1.55	0.30	2.03	0.47	0.40	0.46
Adenosine	0.40	1.58	0.44	1.68	0.42	2.06	0.46	2.39	0.76	0.68	0.74
Cytidine	0.54	3.60	0.55	3.71	0.57	6.33	0.57	7.96	1.08	0.97	1.12
Guanosine	0.38	2.97	0.48	3.40	0.44	6.20	0.51	7.61	0.93	0.90	0.96
Inosine	0.38	2.56	0.46	2.79	0.43	4.40	0.49	6.27	0.85	0.82	0.88
Thymidine	0.27	0.77	0.30	0.76	0.29	0.94	0.31	1.03	0.38	0.41	0.40
Uridine	0.24	0.94	0.29	1.03	0.29	1.67	0.32	2.15	0.49	0.51	0.49
Acyclovir	0.47	2.67	0.50	3.05	0.50	3.61	0.51	4.99	0.89	0.82	0.90
2'-Deoxyuridine	0.26	0.84	0.30	0.89	0.33	1.30	0.32	1.66	0.45	0.52	0.47
3'-Deoxythymidine	0.26	0.53	0.27	0.50	0.28	0.66	0.30	0.62	0.32	0.40	0.39
2'-Deoxyinosine	0.39	2.05	0.45	2.23	0.45	3.06	0.47	3.81	0.82	0.81	0.82

Table S10. The predicted retention times of test compounds on the chromatographic conditions corresponding to the used DoE matrix over bare silica HILIC column by using QSRR-DOE models.



Figure S2. The residual plots of prediction errors using dual-filtering-based GA-PLS models for test set of 16 nucleosides over all experimental conditions corresponding to the used DOE matrix for zwitterionic, amide, amine, and bare silica systems.

	Zwitterionic		Δ	mide	А	mine	Bare Silica		
	Observed t <sub>R</sub>	Predicted t <sub>R</sub>							
2'-Deoxyadenosine	4.91	5.08	4.46	4.74	4.94	5.06	2.24	2.12	
2'-Deoxycytidine	10.79	12.21	9.10	8.89	12.61	12.97	3.46	3.64	
2',3'-Dideoxyadenosi	3.62	4.19	3.83	3.96	3.47	4.15	2.07	2.03	
2'-Deoxyguanosine	11.60	13.89	7.77	7.65	13.97	14.63	3.09	3.51	
3'-Deoxyguanosine	10.70	13.15	7.57	8.49	12.96	14.67	2.90	3.47	
5'-Methyluridine	4.91	5.62	3.92	4.37	6.12	6.54	1.81	2.01	
Adenosine	6.17	6.10	5.06	5.15	6.68	6.55	2.37	2.32	
Cytidine	15.00	16.07	10.31	11.07	19.50	18.04	3.96	4.07	
Guanosine	16.29	17.79	9.24	10.09	21.48	19.67	3.45	3.89	
Inosine	10.66	12.55	6.17	8.04	14.38	15.19	2.90	3.40	
Thymidine	3.65	3.95	3.43	3.84	4.16	4.23	1.61	1.75	
Uridine	5.94	5.68	4.06	4.46	7.57	6.15	1.97	2.05	
Acyclovir	9.89	10.42	6.54	8.47	11.32	10.52	3.14	3.12	
2'-Deoxyuridine	4.26	4.78	3.53	3.91	4.89	5.58	1.74	1.94	
3'-Deoxythymidine	2.61	3.08	2.90	3.26	2.77	3.57	1.40	1.61	
2'-Deoxyinosine	7.80	8.31	5.32	5.99	9.51	8.99	2.70	2.79	

Table S11. The experimental retention data and predicted retention times of test compounds on the selected working conditions over zwitterionic, amide, amine, and bare silica HILIC columns by using QSRR-DOE models.